markets · · globenewswire.com
Persica Pharmaceuticals presents antibiotic exposure-response analysis at the International Society of Pain & Neuroscience (ISPN) Annual Conference
London, UK, 22 October 2026 - Persica Pharmaceuticals Limited ("Persica"), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), today announces presentation of a poster at the Annual Conference of the International Society of Pain and Neuroscience (ISPN) in Amsterdam on 22 October 2026.
London, UK, 22 October 2026 - Persica Pharmaceuticals Limited ("Persica"), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), today announces presentation of a poster at the Annual Conference of the International Society of Pain and Neuroscience (ISPN) in Amsterdam on 22 October 2026.
- #STOCK